CXO leading companies' net profits surge by 3 times! Strong fundamental recovery, Hong Kong Stock Connect healthcare and Hong Kong Stock Connect innovative drugs continue to strengthen over consecutive days

NightAirdropper · 2026-04-01T18:57:16+00:00

On March 31, the AH healthcare sector continued to rise, with Hong Kong stocks in the healthcare industry performing strongly, especially two popular ETFs surging significantly. CXO companies Zhaoyan New Drug and Kelun Pharma released their annual reports, both achieving substantial growth, which drove their stock prices up. Analysts believe that the CXO industry fundamentals have improved, and there may be recovery opportunities in the future. Investors are advised to pay attention to Hong Kong healthcare stock investments.

NightAirdropper

2026-04-01 18:57:16

Abstract generation in progress

March 31, the AH Medical sector continued to rise, and the momentum in Hong Kong-listed healthcare stocks was even stronger. Among popular ETFs, Hong Kong Stock Connect Healthcare Core Assets — Huabao (159137) Hong Kong Stock Connect Medical ETF — once rose more than 2.3%, and Huabao (520880) Hong Kong Stock Connect Innovative Drug ETF, which tracks 100% innovative drug R&D targets, opened higher and then rose to nearly 2%. What is worth paying attention to is that in recent days, the Hong Kong medical and pharmaceutical sectors have delivered a round of sustained rebound.

Late yesterday evening, two CXO companies released their annual reports. Innovent New Drug in 2025 achieved attributable net profit of nearly RMB 300 million, a year-over-year surge of 3 times; while Kelaiying saw both revenue and net profit grow, with attributable net profit reaching RMB 1.132 billion, up 19.35% year over year. At present, Innovent New Drug and Kelaiying both jumped higher in response.

The team from Zheshang Pharmaceutical analyzed that with the CXO industry continuing to clear out and share prices staying relatively low, the team is optimistic about bottom-picking opportunities for local leading CDMO companies and CRO firms benefiting from the recovery in domestic demand. Based on financial, demand, and supply data, the fundamental inflection point for CXO has already emerged and is expected to continue to recover.

Laying in positions at low levels to catch the opportunity for a rebound in Hong Kong-listed pharmaceutical and healthcare stocks, keep two key tools in mind: Huabao (159137) Hong Kong Stock Connect Medical ETF, which uses about 70% of its portfolio to allocate to CXO + AI healthcare, balancing innovative drugs + medical devices (including brain-computer interfaces). Its top ten holdings include scarce internet healthcare leaders such as JD Health and Alibaba Health. Huabao (520880) Hong Kong Stock Connect Innovative Drug ETF, which allocates 100% to innovative drug research and development companies. Its top ten holdings account for more than 70%, with a strong leading-company profile.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.